S7326
SB 657510
≥98% (HPLC)
别名:
2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide, SB-657510
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H22BrClN2O5S
化学文摘社编号:
分子量:
505.81
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: ≥30 mg/mL
创始人
GlaxoSmithKline
储存温度
room temp
SMILES字符串
COc1cc(Br)c(cc1OC)S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2
InChI
1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1
InChI key
KQCZCINJGIRLCD-CYBMUJFWSA-N
应用
SB 657510 may be used to study the urotensin II receptor-mediated signaling.
生化/生理作用
SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist.
SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1
SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.
特点和优势
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
A M D Watson et al.
Diabetologia, 56(5), 1155-1165 (2013-01-25)
The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed. Endothelial cells were grown in normal- and high-glucose (5 and 25 mmol/l) media with and without UII
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持